Literature DB >> 23904830

Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Matteo Lazzeroni1, Davide Serrano.   

Abstract

Cancer vaccines are an emerging therapeutic and prophylactic modality that may play a more important role in cancer prevention and treatment in the future. Therapeutic cancer vaccines are designed to generate a targeted, immune-mediated antitumor response. Successful prophylactic vaccines are those against oncogenic viral infections, such as the human papillomavirus and cervical cancer. However, a tough challenge for the majority of tumor vaccines is the self-nature of tumor antigens. Ongoing studies are investigating methods to enhance vaccine strategies including immune-modulating agents. The present review analyzes the potential use of vaccines in the primary prevention of breast cancer, focusing on the recent extension of vaccine target selection to self-proteins that are overexpressed during the early stages of tumor development but whose expression no longer occurs as we age, a feature that may avoid clinically significant autoimmune sequelae.

Entities:  

Keywords:  Breast cancer prevention; Vaccines

Year:  2012        PMID: 23904830      PMCID: PMC3515785          DOI: 10.1159/000342167

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  75 in total

1.  HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

Authors:  Ning Liao; Guo-chun Zhang; Yan-hui Liu; Xue-rui Li; Meng Yao; Fang-ping Xu; Li Li; Yi-long Wu
Journal:  Pathol Res Pract       Date:  2010-11-20       Impact factor: 3.250

Review 2.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

3.  Prophylactic cancer vaccination by targeting functional non-self.

Authors:  Vincent K Tuohy; Ritika Jaini
Journal:  Ann Med       Date:  2011-06-09       Impact factor: 4.709

Review 4.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 5.  Causality in medicine: the case of tumours and viruses.

Authors:  V Vonka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-12-29       Impact factor: 6.237

6.  Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.

Authors:  Axel Mischo; Boris Kubuschok; Kubilay Ertan; Klaus-Dieter Preuss; Bernd Romeike; Evi Regitz; Claudia Schormann; Diederik de Bruijn; Andreas Wadle; Frank Neumann; Werner Schmidt; Christoph Renner; Michael Pfreundschuh
Journal:  Int J Cancer       Date:  2006-02-01       Impact factor: 7.396

7.  Sequence of the murine alpha-lactalbumin-encoding cDNA: interspecies comparison of the coding frame and deduced pre-protein.

Authors:  J L Vilotte; S Soulier; J C Mercier
Journal:  Gene       Date:  1992-03-15       Impact factor: 3.688

8.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Authors:  A Ringberg; L Anagnostaki; H Anderson; I Idvall; M Fernö
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

9.  HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Authors:  Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

10.  Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

Authors:  Matteo Brunelli; Erminia Manfrin; Guido Martignoni; Keith Miller; Andrea Remo; Daniela Reghellin; Samantha Bersani; Stefano Gobbo; Albino Eccher; Marco Chilosi; Franco Bonetti
Journal:  Am J Clin Pathol       Date:  2009-05       Impact factor: 2.493

View more
  5 in total

1.  Immunotherapy in breast cancer - towards a new understanding of both tumor and host.

Authors:  Peter C Dubsky; Giuseppe Curigliano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 2.  Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.

Authors:  Davide Serrano; Matteo Lazzeroni; Bernardo Bonanni
Journal:  Mol Oncol       Date:  2014-12-20       Impact factor: 6.603

3.  Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study.

Authors:  Silvia Delgado-García; Juan-Carlos Martínez-Escoriza; Alfonso Alba; Tina-Aurora Martín-Bayón; Hortensia Ballester-Galiana; Gloria Peiró; Pablo Caballero; Jose Ponce-Lorenzo
Journal:  BMC Cancer       Date:  2017-05-08       Impact factor: 4.430

Review 4.  The oncogenic potential of human cytomegalovirus and breast cancer.

Authors:  Georges Herbein; Amit Kumar
Journal:  Front Oncol       Date:  2014-08-25       Impact factor: 6.244

5.  Evaluation of human cytomegalovirus antigen expression in invasive breast carcinoma in a population of Iranian patients.

Authors:  Fereshteh Mohammadizadeh; Fatemeh Mahmudi
Journal:  Infect Agent Cancer       Date:  2017-06-26       Impact factor: 2.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.